Compare CubeSmart (CUBE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Incyte Corporation — how do they compare? CubeSmart trades at $40.56 (market cap $9.19B), while Incyte Corporation trades at $112.62 (market cap $22.82B). The key difference: Incyte Corporation is far larger — about 2.5× CubeSmart's market cap, and CubeSmart pays a 5.22% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CUBE | INCY | |
|---|---|---|
Market Cap | $9.19B | $22.82B |
Sector | Real Estate | Health |
52-Week High | $42.34 | $118.52 |
52-Week Low | $35.36 | $67.38 |
Enterprise Value | $12.69B | $18.85B |
Dividend Yield | 5.22% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
